Compare TAK & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAK | GEHC |
|---|---|---|
| Founded | 1781 | 1892 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3B | 37.7B |
| IPO Year | N/A | N/A |
| Metric | TAK | GEHC |
|---|---|---|
| Price | $15.89 | $85.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $87.20 |
| AVG Volume (30 Days) | 2.4M | ★ 2.6M |
| Earning Date | 01-29-2026 | 02-04-2026 |
| Dividend Yield | ★ 3.34% | 0.16% |
| EPS Growth | N/A | ★ 32.35 |
| EPS | 0.14 | ★ 4.83 |
| Revenue | ★ $29,846,840,032.00 | $20,246,000,000.00 |
| Revenue This Year | N/A | $6.33 |
| Revenue Next Year | $0.47 | $4.34 |
| P/E Ratio | $113.33 | ★ $17.95 |
| Revenue Growth | N/A | ★ 3.51 |
| 52 Week Low | $12.80 | $57.65 |
| 52 Week High | $15.97 | $94.80 |
| Indicator | TAK | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 77.29 | 60.64 |
| Support Level | $15.48 | $81.94 |
| Resistance Level | $15.78 | $84.07 |
| Average True Range (ATR) | 0.17 | 1.41 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 94.15 | 68.30 |
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).